Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
Journal
The New England journal of medicine
ISSN: 1533-4406
Titre abrégé: N Engl J Med
Pays: United States
ID NLM: 0255562
Informations de publication
Date de publication:
27 10 2022
27 10 2022
Historique:
pubmed:
13
9
2022
medline:
1
11
2022
entrez:
12
9
2022
Statut:
ppublish
Résumé
In a pilot study involving patients with cutaneous squamous-cell carcinoma, a high percentage of patients had a pathological complete response with the use of two doses of neoadjuvant cemiplimab before surgery. Data from a phase 2 study are needed to confirm these findings. We conducted a phase 2, confirmatory, multicenter, nonrandomized study to evaluate cemiplimab as neoadjuvant therapy in patients with resectable stage II, III, or IV (M0) cutaneous squamous-cell carcinoma. Patients received cemiplimab, administered at a dose of 350 mg every 3 weeks for up to four doses, before undergoing surgery with curative intent. The primary end point was a pathological complete response (the absence of viable tumor cells in the surgical specimen) on independent review at a central laboratory, with a null hypothesis that a pathological complete response would be observed in 25% of patients. Key secondary end points included a pathological major response (the presence of viable tumor cells that constitute ≤10% of the surgical specimen) on independent review, a pathological complete response and a pathological major response on investigator assessment at a local laboratory, an objective response on imaging, and adverse events. A total of 79 patients were enrolled and received neoadjuvant cemiplimab. On independent review, a pathological complete response was observed in 40 patients (51%; 95% confidence interval [CI], 39 to 62) and a pathological major response in 10 patients (13%; 95% CI, 6 to 22). These results were consistent with the pathological responses determined on investigator assessment. An objective response on imaging was observed in 54 patients (68%; 95% CI, 57 to 78). Adverse events of any grade that occurred during the study period, regardless of whether they were attributed to the study treatment, were observed in 69 patients (87%). Grade 3 or higher adverse events that occurred during the study period were observed in 14 patients (18%). Neoadjuvant therapy with cemiplimab was associated with a pathological complete response in a high percentage of patients with resectable cutaneous squamous-cell carcinoma. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov number, NCT04154943.).
Sections du résumé
BACKGROUND
In a pilot study involving patients with cutaneous squamous-cell carcinoma, a high percentage of patients had a pathological complete response with the use of two doses of neoadjuvant cemiplimab before surgery. Data from a phase 2 study are needed to confirm these findings.
METHODS
We conducted a phase 2, confirmatory, multicenter, nonrandomized study to evaluate cemiplimab as neoadjuvant therapy in patients with resectable stage II, III, or IV (M0) cutaneous squamous-cell carcinoma. Patients received cemiplimab, administered at a dose of 350 mg every 3 weeks for up to four doses, before undergoing surgery with curative intent. The primary end point was a pathological complete response (the absence of viable tumor cells in the surgical specimen) on independent review at a central laboratory, with a null hypothesis that a pathological complete response would be observed in 25% of patients. Key secondary end points included a pathological major response (the presence of viable tumor cells that constitute ≤10% of the surgical specimen) on independent review, a pathological complete response and a pathological major response on investigator assessment at a local laboratory, an objective response on imaging, and adverse events.
RESULTS
A total of 79 patients were enrolled and received neoadjuvant cemiplimab. On independent review, a pathological complete response was observed in 40 patients (51%; 95% confidence interval [CI], 39 to 62) and a pathological major response in 10 patients (13%; 95% CI, 6 to 22). These results were consistent with the pathological responses determined on investigator assessment. An objective response on imaging was observed in 54 patients (68%; 95% CI, 57 to 78). Adverse events of any grade that occurred during the study period, regardless of whether they were attributed to the study treatment, were observed in 69 patients (87%). Grade 3 or higher adverse events that occurred during the study period were observed in 14 patients (18%).
CONCLUSIONS
Neoadjuvant therapy with cemiplimab was associated with a pathological complete response in a high percentage of patients with resectable cutaneous squamous-cell carcinoma. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov number, NCT04154943.).
Identifiants
pubmed: 36094839
doi: 10.1056/NEJMoa2209813
pmc: PMC9844515
mid: NIHMS1860416
doi:
Substances chimiques
cemiplimab
6QVL057INT
Antineoplastic Agents, Immunological
0
Banques de données
ClinicalTrials.gov
['NCT04154943']
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1557-1568Subventions
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
Copyright © 2022 Massachusetts Medical Society.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Plast Reconstr Aesthet Surg. 2021 Mar;74(3):625-631
pubmed: 33189623
BMJ Case Rep. 2019 Aug 30;12(8):
pubmed: 31471358
J Neurol Surg B Skull Base. 2020 Oct;81(5):585-593
pubmed: 33134027
J Clin Oncol. 2020 Sep 1;38(25):2916-2925
pubmed: 32673170
Ear Nose Throat J. 2022 Dec;101(10):663-667
pubmed: 33314982
J Thorac Oncol. 2020 Aug;15(8):1281-1297
pubmed: 32522713
Clin Cancer Res. 2021 Aug 15;27(16):4557-4565
pubmed: 34187851
Lancet Oncol. 2020 Feb;21(2):294-305
pubmed: 31952975
Eye (Lond). 2017 Mar;31(3):379-388
pubmed: 27768120
N Engl J Med. 2022 May 26;386(21):1973-1985
pubmed: 35403841
N Engl J Med. 2018 Jul 26;379(4):341-351
pubmed: 29863979
Curr Oncol Rep. 2021 Aug 27;23(11):125
pubmed: 34448958
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
N Engl J Med. 2018 Jul 26;379(4):363-374
pubmed: 30044931
J Immunother Cancer. 2021 Aug;9(8):
pubmed: 34413166
Otolaryngol Head Neck Surg. 2014 Apr;150(4):610-7
pubmed: 24474713
J Am Acad Dermatol. 2018 Feb;78(2):249-261
pubmed: 29332705
Nat Med. 2021 Feb;27(2):301-309
pubmed: 33558722
Eur Arch Otorhinolaryngol. 2022 Apr;279(4):2069-2075
pubmed: 34223976
Ann Oncol. 2018 Aug 1;29(8):1853-1860
pubmed: 29982279